Full-Time

Quality Systems Specialist II

Document Control

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

501-1,000 employees

Develops cortisol modulators for medical conditions

Compensation Overview

$105.3k - $123.9k/yr

Senior

San Carlos, CA, USA

Hybrid position requiring on-site presence 3 days per week.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Zendesk
Google Cloud Platform
Requirements
  • Strong working knowledge of GMP and GCP practices and how they might apply to Corcept SOPs, work instructions, and controlled records
  • Strong grasp of different document types such protocols, reports, controlled records (development, clinical, and commercial), vendor/supplier audit documentation, and clinical study level documents
  • Strong understanding of version and revision control for a variety of controlled document types
  • Fluent in Veeva QDS workflows, lifecycles, and audit trails
  • Working knowledge of various controlled documents and their purpose across a pharmaceutical drug development cycle
  • Strong working knowledge of change controls, deviations, investigations, CAPAs, complaints, and internal/external audits
  • Strong grasp of GxP training program requirements, including role-based training, curricula hierarchy, instructor led training, and training assignments
  • Ability to promptly respond to email inquiries and user support questions using ticketing systems like Zendesk
Responsibilities
  • Provide user assistance, training, and oversight on document control and record management systems, processes, and procedures
  • Organize, maintain, and continuously update a library of knowledge-based articles and FAQs from instructions developed by Quality Systems team members
  • Act as first point of contact for all Corcept users in Veeva QDS
  • Perform administrative tasks to maintain both the electronic document management system (Veeva QualityDocs) and legacy paper-based systems, including but not limited to cataloging on-site documents, executing the certified copy process, and helping maintain a global glossary list
  • Process document change controls (DCCs) for broad variety of controlled documents
  • Initiate the document periodic review process across various SOP owners and convert data for pending and overdue periodic review tasks into reportable metrics
  • Identify and escalate gaps and discrepancies in controlled documents and the processes that govern them (e.g. document formatting, SOP style consistency, clear and concise wording, document change controls, etc.)
  • Enforce guidelines on document metadata and company processes to maintain consistency and uniformity in Veeva QDS
  • Assist users with formatting documents such as SOPs, work instructions, or quality agreements using approved templates and finalizing controlled forms
  • Support/execute processes for filing, organizing, and cataloging legacy paper documents
Desired Qualifications
  • Experience with Electronic Document Management and Learning Management Systems (specifically, Veeva Quality suite and ComplianceWire LMS)
  • Proficient in the use of MS Office applications (Excel, Word, Visio, Teams)
  • Skilled at formatting documents in accordance with templates and capable of producing controlled forms
  • Excellent organizational skills and the ability to manage multiple competing tasks
  • Excellent communication skills with the ability to collaborate with a wide range of stakeholders in various departments
  • BA/BS degree in a scientific/technical/engineering field
  • Minimum of 6 years of experience in pharmaceutical or life sciences organizations

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is an FDA-approved medication for Cushing's syndrome, a condition caused by excessive cortisol. Corcept has created over 1,000 unique cortisol modulators through extensive research and development. Unlike many competitors, Corcept emphasizes both drug development and patient education, providing resources to healthcare professionals and patients to enhance understanding of cortisol-related disorders. The company's goal is to improve treatment options for patients with serious medical conditions linked to cortisol imbalance.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Corcept's stock is the best performing pharma stock in 2025.
  • The MOMENTUM trial could expand Corcept's market reach.
  • Recent investments show growing confidence in Corcept's future prospects.

What critics are saying

  • Securities fraud investigations could lead to legal and financial repercussions.
  • Teva's antitrust lawsuit may result in legal challenges.
  • Potential reputation damage from ongoing legal investigations.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few competitors.
  • Korlym is the first FDA-approved treatment for Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

1%

2 year growth

-3%
Access News Wire
Mar 18th, 2025
Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi & Korsinsky about Securities Fraud Investigation - CORT

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws.

Stock Titan
Mar 10th, 2025
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension.

PR Newswire
Mar 3rd, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Insider Monkey
Feb 23rd, 2025
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma stock So Far in 2025.

Investing.com
Dec 30th, 2024
Corcept files NDA for new Cushing's syndrome drug

Corcept introduced Korlym(R), the first FDA-approved treatment for Cushing's syndrome, in February 2012.